# Cancer Signaling Networks Research Program

> **NIH NIH P30** · YALE UNIVERSITY · 2024 · $81,519

## Abstract

CANCER SIGNALING NETWORKS RESEARCH PROGRAM
PROGRAM CODE: CSN
PROJECT SUMMARY/ABSTRACT
Cancer Signaling Networks (CSN) is a transdisciplinary research program that leverages advances in knowledge
of signaling networks to develop groundbreaking therapies that address clinical needs. The Program includes
world-class investigators who study fundamental aspects of signaling and metabolic networks relevant to cancer
and who develop novel technologies to study signaling that can be harnessed for basic and translational cancer
research. CSN clinical investigators provide expertise with signaling targeting agents in the clinic and bring
patient-driven perspectives to the program. CSN initiates and facilitates research activities and collaborations
across three overarching programmatic synergistic themes: cancer metabolism, metastasis and drug
resistance. These areas of strategic focus leverage program member’s expertise to overcome challenges in
treating YCC priority cancers for our catchment area, including lung, breast, prostate and liver cancer
that have higher (or rising) incidence in CT, and/or disproportionately affect specific populations. CSN research
priorities also address disparities-associated risk factors and co-morbidities in our catchment area. These
align with YCC priorities including cancers tied to metabolism (obesity and fatty/fibrotic liver syndrome-
associated cancers) and tobacco use (smoking-related malignancies). CSN Aims are to: 1) Elucidate intra-
cellular signaling and metabolic networks that contribute to cancer; 2) Understand how cells communicate with
one another and with the microenvironment during malignant progression; and 3) Exploit this knowledge to
identify new therapeutic targets, improve impact of existing agents, and overcome treatment resistance. In
pursuit of our Aims, CSN investigators pioneer cutting edge spatial profiling technologies, sensitive biomarker
assays, and novel model systems. With our efforts to assemble unique biorepositories of patient specimens, we
are well positioned to enable further high-impact discoveries. CSN has 51 members from 16 different Yale
departments. Funding is robust, with total cancer-focused funding of $12.9M (direct costs) including $9.8M in
peer-reviewed funding, $4.0M from the NCI. Program members published 399 papers during this award period
of which 44% are high impact and include both inter-programmatic (37%) and intra-programmatic (14%)
collaborations. We are focused on expanding intra-programmatic collaborations in strategic areas, an effort
which has recently yielded multi-PI grants – with others being submitted. CSN members also lead training and
mentorship initiatives for the next generations of cancer researchers. Finally, since the last cycle, CSN members
play key roles in the Yale SPOREs and provide leadership on clinical trials. CSN members are also involved in
vigorous inter-programmatic collaborations – most notably with Developmental Therapeutics (DT) – to promot...

## Key facts

- **NIH application ID:** 10934038
- **Project number:** 2P30CA016359-44
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** KATERINA Abigail POLITI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $81,519
- **Award type:** 2
- **Project period:** 1997-07-01 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10934038

## Citation

> US National Institutes of Health, RePORTER application 10934038, Cancer Signaling Networks Research Program (2P30CA016359-44). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10934038. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*